Spanish Biotech Stock News

BME:TRE
BME:TREEnergy Services

Técnicas Reunidas (BME:TRE) Stock Trails Profit Growth On Project Risk

Técnicas Reunidas came into this earnings day with a bruised share price, down roughly 20% over three months, yet trading on a modest 14x P/E and far below one prominent fair value estimate. The stock closed at €28.28 after the release, as investors weighed headline growth against lingering project risk. The real story in this quarter is profit quality. Q2 revenue of €1,478.1m and net income of €44.4m sit within a half year that includes a €45m provision linked to the Middle East conflict,...
BME:SCYR
BME:SCYRConstruction

Sacyr (BME:SCYR) Stock Looks Cheap as Concession Cash Builds

Sacyr entered this earnings week with the stock treading water, up only slightly over the past month and almost flat over three months. That calm surface hides a much stronger profit story underneath. Q2 basic earnings per share came in at €0.051, ahead of Q1, and net income reached €40.8m on revenue of €1.32b. The headline this quarter is profit momentum in a business often treated as a slow, contract driven grinder. The next sections unpack whether that earnings strength justifies where the...
BME:BBVA
BME:BBVABanks

BBVA (BME:BBVA) Stock Rallies Behind Loan Growth And Fresh Buybacks

BBVA stock closed at €24.2 after the market weighed in on its Q2 2026 numbers that delivered a punchy headline. The group posted net income of €3.062b for the quarter and €6.051b for the first half, with return on tangible equity around the low 20s that management calls best in class among big European banks. Short term traders are focused on the recent double digit share price gains. Long term investors are looking at a bank combining strong profitability with rising loans and a growing...
BME:ACS
BME:ACSConstruction

ACS (BME:ACS) Stock Slips As Strong Growth Meets Valuation Doubts

ACS Actividades de Construcción y Servicios stock has drifted lower in recent weeks, down about 11% over the past month, even as the price sits near €110 after the latest results. The short term mood looks cautious, but the earnings print tells a different story. Q2 revenue reached about €13.8b with basic earnings per share just over €1.05, and trailing 12 month earnings now sit above €1b. The key point for ACS is valuation. The stock trades on a P/E above the European construction average,...
BME:CIRSA
BME:CIRSAHospitality

Cirsa Enterprises (BME:CIRSA) Stock Faces A Profit Rebuild Against Debt Doubts

Cirsa Enterprises stock has climbed steadily into this earnings season, with gains over the past week and month setting expectations high. The headline is not the share price. It is the profit rebuild. Net income from continuing operations over the last twelve months now sits above €160m, with net profit margin at 4.7% compared with just 0.6% a year earlier. The market is treating Cirsa as a financially stretched casino operator, focused on weak interest and dividend coverage, while the core...
BME:PUIG
BME:PUIGPersonal Products

Puig Brands (BME:PUIG) Stock Faces Margin Questions Despite Record First Half Revenue

Puig Brands walked into this earnings day with a stock that had slipped over the past three months yet traded on a P/E well below peers and below some fair value estimates. That set the stage for an emotion heavy session. The headline from the numbers is clear. Record first half net revenues of €2.35b and an adjusted EBITDA margin of 19.5% landed alongside an adjusted net profit of €260m. Investors now need to decide whether a lower valuation still reflects caution or if today’s beauty...
BME:MRL
BME:MRLREITs

Is MERLIN Properties SOCIMI (BME:MRL) Cheap Following Strong Half Year Results And Higher Guidance?

MERLIN Properties SOCIMI (BME:MRL) has just reported its half year 2026 earnings, with higher sales, net income and earnings per share, and an increased full year FFO guidance that highlights current business momentum. See our latest analysis for MERLIN Properties SOCIMI. The current share price of MERLIN Properties SOCIMI at €14.86 comes after a 1-day share price return of 2.48%. The year to date share price return of 20.52% and 1-year total shareholder return of 25.39% indicate momentum...
BME:PHM
BME:PHMBiotechs

Pharma Mar (BME:PHM) Stock Faces Clinical Setback Despite Royalty Strength

Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat near term share price against a very different earnings picture. The company delivered resilient recurring oncology revenues and stayed cash generative, yet quarterly profit slipped into a small loss of €0.972m even as trailing twelve month earnings from continuing operations reached €56.126m. The real story now sits on the longer horizon. Royalty growth, the Zepzelca...
BME:SCYR
BME:SCYRConstruction

Sacyr (BME:SCYR) Earnings And Dividend Lift Keep Undervaluation In Focus

Sacyr (BME:SCYR) is back in focus after reporting half year 2026 results, with revenue and EBITDA up around 9%, net profit lifted by a Colombia divestment, and higher cash dividends attracting fresh investor attention. See our latest analysis for Sacyr. Sacyr’s recent half year 2026 earnings update comes after a strong run, with the share price at €4.824 and a year to date share price return of 22.87%, alongside a 1 year total shareholder return of 38.08% and 5 year total shareholder return...
BME:OLE
BME:OLEFood

Deoleo (BME:OLE) Stock Profit Revival Leans On One Off Gain

Deoleo stock inched into this earnings day with a 30 day gain of about 13% and a modest 7 day slip, reflecting investors testing a cautious recovery story rather than a runaway rally. The headline from this half year update is simple. Profitability is real but flattered by a €15.8m one off gain sitting inside the trailing 12 month numbers. For a low priced, roughly €0.34 stock trading on a single digit P/E ratio, that mix of cleaner profits and one off help is exactly what the market now has...
BME:TEF
BME:TEFTelecom

Telefónica (BME:TEF) Stock Price Hinges On Cash Flow And Debt

Telefónica comes into this earnings day as a deeply discounted telecom stock, with the share price at €3.602 and 90‑day returns down about 7%. The market has treated it as a high yield, high risk turnaround. The Q2 print keeps that tension alive. The group delivered €8,576m of revenue and positive quarterly earnings per share of €0.11 while still carrying a trailing 12 month loss and heavy interest burden. For investors, the headline is simple: cash generation and debt coverage now matter...
BME:VIS
BME:VISFood

Viscofan (BME:VIS) Stock Commands A Premium Despite Softer Quarterly Profit

Viscofan shares came into this earnings print looking tired, roughly flat over the past week and down over the past quarter, even as valuation sat above peer P/E levels. The market had already priced in some caution. The headline from this quarter is margin resilience, with Q2 net income of €37.654 million on €329.325 million of revenue and trailing 12 month earnings from continuing operations of €159.73 million. The question now is whether that earnings power justifies investors paying a...
BME:ELE
BME:ELEElectric Utilities

Endesa (BME:ELE) Stock Can Stronger Margins Outrun Earnings Pressure

Endesa stock came into these results quietly bid, up about 9.2% over the past three months and closing at €41.7 yesterday. The earnings headline is not the revenue line. The story is the profit engine. Net income for Q2 landed at €745m with basic earnings per share of €0.73, while trailing net margin over the last 12 months sits at 12.4%. For short term traders that might look like a decent quarter. For anyone thinking in years rather than days, the key question is how that stronger margin...
BME:EBRO
BME:EBROFood

Ebro Foods (BME:EBRO) Stock Finds Support In Rising Margins

Ebro Foods stock closed at €18.26 after the Q2 2026 report, with only modest moves in recent weeks. The market reaction looks muted, yet the results tell a more loaded story. Quarterly net income of €50.93m sits against a trailing twelve month profit of €221.77m, and the stock trades on a P/E of 12.7x compared with higher peer and industry multiples. For long term holders, the real headline is that earnings over the past year grew faster than revenue, which lifted net margin to 7.5% and...
BME:RED
BME:REDElectric Utilities

Redeia (BME:RED) Stock Sees Revenue Growth Clash With Softer Profit Margins

Redeia Corporación went into this print priced for steadiness, with the stock roughly flat over the past quarter. The latest move around €15.32 shows investors still testing that slow growth, high income story. The headline from Q2 is a squeeze on profitability. Quarterly net income of €123.7 million sits below Q1, even as revenue holds at €458.4 million, and trailing net profit margins are softer than last year. For a regulated grid operator that many holders treat as a bond substitute,...
BME:AENA
BME:AENAInfrastructure

Aena (BME:AENA) Stock Rides Profit Growth As Capex Questions Persist

Aena S.M.E stock went into this earnings print with a flat month behind it and a strong 90 day run of about 15%. Today the real story sits in the profit engine. Quarterly net income reached €672.5m on revenue of €1.8b, which keeps margins and earnings firmly in focus for a business that depends on traffic volume and pricing power. The question for investors now is simple: Did a stock that has already rerated higher get results strong enough to justify that optimism, or has sentiment run ahead...
BME:CABK
BME:CABKBanks

CaixaBank (BME:CABK) Stock Faces Margin Pressure Despite Strong Profit Growth

The market came into today still digesting CaixaBank’s strong run, with the stock up about 15% over the past three months and now sitting at €12.48. The latest quarter delivered another heavy profit print, with Q2 net income of €1.631b and a group return on tangible equity around 18% for the first half. That kind of earnings engine matters more than the day’s price flicker. The real story for long term holders is whether this level of profitability can justify a P/E that already sits above...
BME:ART
BME:ARTElectrical

Arteche Lantegi Elkartea (BME:ART) Stock Price Slips Despite Margin Surge

Arteche Lantegi Elkartea went into this earnings print with a bruised share price, down about 12% over the past month and 7% over the past quarter, even as investors had been told a strong growth story. The earnings headline is clear. Profitability did the heavy lifting. Net income from continuing operations over the last twelve months reached €58.051m and the reported net profit margin moved to 10.1%. The question now is whether a market that has been selling the stock is underpricing a...
BME:PHM
BME:PHMBiotechs

Pharma Mar (BME:PHM) Faces An Earnings Test As Investors Weigh Its Valuation

Pharma Mar (BME:PHM) is back in focus after reporting first half 2026 earnings, with net income of €0.561 million compared with €19.42 million for the same period a year earlier. See our latest analysis for Pharma Mar. Pharma Mar's recent half year net income figure has come alongside a 10.81% 1 month share price return to €81.0. However, the share price is still down 15.62% over three months, while the 3 year total shareholder return of 149.26% remains strong. This suggests momentum has...
BME:FER
BME:FERConstruction

Is Ferrovial (BME:FER) Fully Priced Following Strong Highways Growth And The JFK Delay?

Ferrovial stock reaction to strong highways performance and JFK delay Ferrovial (BME:FER) is in focus after its first half 2026 update, which combined double digit revenue and adjusted EBITDA growth from North American highways with an extended construction backlog and a delay at JFK's New Terminal 1. See our latest analysis for Ferrovial. Ferrovial's recent half year results and the JFK delay arrive after a period where short term share price momentum has eased, with the 30 day share price...
BME:COXG
BME:COXGRenewable Energy

Cox Infrastructure Group (BME:COXG) Stock Revenue Climbs As Losses Deepen

Cox Infrastructure Group shares came into this earnings print on the back foot, with the stock down around 6% over the past month, yet the headline story is not the share price. The real shock is on the income line. Over the last twelve months the company swung from profit to a loss of €56.8 million, even as revenue reached €1.53b. That profit squeeze is what the market is trying to price in today, and it sets the emotional tone for how investors will read the rest of this report. Concerned...